Member Updates

Within the BSCC network there exists extensive knowledge and expertise. We are always eager to share relevant knowledge, news and useful information. This week we are happy to share updates from GSK, Essity, and Saab.

GSK

GSK invested £50 million into a five-year collaboration with the University of Cambridge and Cambridge University Hospitals. This collaboration aims to advance treatments for immune-related diseases, with a focus on kidney and respiratory illnesses. Leveraging Cambridge’s academic and clinical expertise along with GSK’s strengths in immune science and AI-driven drug development, CG-TIC will work to better understand disease mechanisms and speed up therapy development.

Essity

Essity were named a Diversity Leader by the Financial Times for the fourth consecutive year. This recognition, based on a Statista survey of over 100,000 employees across European companies, honours companies excelling in five key diversity areas: gender, sexual orientation, age, ethnicity, and disability.

Saab

Saab has secured a £20 million contract amendment with the UK’s Ministry of Defence to support British Army training in Oman. This agreement, running from 2024 to 2025, will provide advanced training equipment that realistically simulates combat scenarios, allowing soldiers to review and improve their performance. Saab’s team will also oversee the training environment and ensure equipment reliability throughout.